Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CBMG $22.56 3.1600 +16.29%
ADXS $4.27 0.3900 +10.05%
ARWR $15.34 0.7700 +5.28%
ARGS $9.83 0.4400 +4.69%
AMBI $7.92 0.3500 +4.62%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

EXEL $1.85 -2.2900 -55.31%
ZIOP $3.00 -0.2300 -7.12%
IDRA $2.70 -0.1900 -6.57%
ONCY $1.30 -0.0800 -5.80%
Kite $26.82 -1.4500 -5.13%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 877 | 878 | 879 | 880 | 881 | 882 | 883 | 884 | 885 | 886 | Next > | Last >>

Harbor BioSciences Wraps Up Phase I/IIa Prostate Cancer Study

(Harbor BioSciences) Feb 7, 2011 – Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.
read press release 

EpiCept Reports Positive Results From EpiCept™ NP-1 Trial In Patients With Chemotherapy-Induced Peripheral Neuropathy

(TheStreet) Feb 7, 2011 - EpiCept Corporation today announced positive results from a Phase IIb trial evaluating the efficacy and safety of EpiCept™ NP-1 (NP-1) in chemotherapy-induced peripheral neuropathy (CPN).
read article 

Helix Gets FDA IND Approval To Conduct U.S. Phase I Clinical Study With L-DOS47

(Morningstar) Feb 7, 2011 - Helix BioPharma Corp. today announced that it has received approval for its investigational new drug ("IND") application from the United States Food and Drug Administration ("FDA") to perform its planned U.S. Phase I clinical safety and tolerability study of its lung cancer drug candidate L-DOS47.
read article 

Marina Biotech and The Debiopharm Group Partner to Develop and Commercialize RNAi-Based Therapies for the Treatment of Bladder Cancer

(Morningstar) Feb 3, 2011 - The Debiopharm Group and Marina Biotech, Inc. announced today that they entered into an exclusive agreement concerning the development and commercialization of Marina Biotech's pre-clinical program in bladder cancer.
read article 

Progenics Pharmaceuticals and Salix Pharmaceuticals Announce Worldwide License Agreement for RELISTOR®

(Yahoo! Finance) Feb 7, 2011 - Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that they have entered into an exclusive worldwide (except Japan) agreement by which Salix has licensed rights to RELISTOR® (methylnaltrexone bromide).
read article 

Sanofi, Genzyme Expect Deal Early This Week

(Wall Street Journal) Feb 7, 2011 - Sanofi-Aventis SA is taking longer than expected on due diligence for its proposed acquisition of Genzyme Corp., but the two companies are confident they can seal a deal early this week, people familiar with the matter said.
read article (paid subscription required) 

Unique Clinical Trial Design Accelerates Personalization of Breast Cancer Treatment

(Georgetown Lombardi) Feb 3, 2011 - An innovative national clinical trial underway at Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center and Georgetown University Hospital, expedites the screening of promising new drugs for women with early stage but high risk breast cancer - women for whom an improvement over standard treatment could dramatically change the odds of survival.
read press release 

Important Information on the Timely Claims Filing Requirement

(COA) Feb 7, 2011 - From CMS...The Centers for Medicare & Medicaid Services (CMS) would like to remind Medicare Fee-For-Service physicians, providers and suppliers submitting claims to Medicare for payment, as a result of the Patient Protection and Affordable Care Act (PPACA), effective immediately, all claims for services furnished on or after Jan 1, 2010, must be filed with your Medicare contractor no later than one calendar year (12 months) from the date of service – or Medicare will deny them.
read article 

CURE Magazine Teams Up With Amgen Oncology and Breakaway from Cancer(R) to Launch 2011 Extraordinary Healer Award for Oncology Nursing

(TradingMarkets) Feb 7, 2011 - For the fifth consecutive year, CURE magazine is calling on cancer patients, survivors and caregivers from across the country to submit essays for the 2011 Extraordinary Healer Award for Oncology Nursing.
read article 

Research Team Honored for Innovative Science to Advance Cancer Research

(AACR) Feb 7, 2011 - The Fifth Annual AACR Team Science Award will be given to a team of internationally renowned molecular biologists, epidemiologists, biostatisticians and clinicians from Fred Hutchinson Cancer Research Center and University of Washington who have worked together on human papillomavirus (HPV) for more than 20 years.
read press release 

Zen Hospice Project: A Portrait of Palliative Care

(UCSF) Feb 3, 2011 - A shrine in the living room honors three past residents.
read press release 

Op-Ed: Pharma Needs U.S. Help

(Boston Globe) Feb 7, 2011 - Important drugs will be slow to market if agencies don’t coordinate.
read article (free registration required) 

Glaxo Adds Safety Restrictions to Avandia Label

(ABC News) Feb 7, 2011 - GlaxoSmithKline says it has updated the labeling of its diabetes pill Avandia to include safety restrictions ordered by federal health authorities because of the drug's links to heart attack.
read article 

FDA Seeks More Data on Failing Jaw Implants

(AP/MSNBC) Feb 7, 2011 - The Food and Drug Administration is looking into reports that jaw implants made by three companies have been failing early, causing patients extreme pain and requiring additional surgeries.
read article 

FDA Clears iPad Radiology App; Doctors, What’s Your Dream App?

(WSJ Health Blog) Feb 7, 2011 - The FDA recently cleared a radiology app for the iPhone and iPad that will let physicians view medical images including MRI, CT and PET scans.
read article 

Roche CEO Defends Avastin Cancer Drug, Despite Scrutiny

(Wall Street Journal) Feb 4, 2011 - Roche Holding AG Chief Executive Severin Schwan defended the drug maker's biggest product, cancer treatment Avastin, as increased regulatory scrutiny of the drug's effectiveness in breast cancer is pressuring sales.
read article (paid subscription required) 

Journal of Clinical Oncology Publishes Clinical Trial Results of VELCADE Combination in Aggressive Subtypes of Non-Hodgkin Lymphoma

(Yahoo! Finance) Feb 4, 2011 - Millennium: The Takeda Oncology Company today announced that Phase II results of a clinical trial examining VELCADE® (bortezomib) in patients with previously untreated aggressive lymphoma were published in the Journal of Clinical Oncology.
read article 

Celgene Shares Fall on Drug Malignancy Concerns

(Reuters) Feb 3, 2011 - Shares of Celgene Corp fell as much as 8 percent on Thursday amid growing concerns that its most important cancer drug, Revlimid, could cause secondary malignancies in some patients with the blood cancer multiple myeloma.
read article 

Ovarian Cancer Spread Missed When Recommended Staging Biopsies Not Performed, UC Davis Researchers Find

(UC Davis) Feb 2, 2011 - Risk of death doubles for those who are not checked for lymph node metastases.
read press release 

Simple Life Changes Could Stop Millions of Cancers

(Reuters) Feb 4, 2011 - About a third of all common cancers in the United States, China and Britain could be prevented each year if people ate healthier food, drank less alcohol and exercised more, health experts said on Friday.
read article 

Blood Pressure Meds Tied to Lower Cancer Risk

(Reuters) Feb 3, 2011 - Doctors in Taiwan have found that people who take a common type of blood pressure drug appear less likely to develop cancer than patients not taking the medication.
read article 

Cell Research Shows Promise in Hard-to-Treat Breast Cancer

( Feb 3, 2011 - A form of fast-spreading breast cancer has remained hard to treat despite overall advances in the field. Now a new study reveals some of the underpinnings of this disease, called basal subtype breast cancer, and may point the way to future avenues of treatments.
read article 

Cancer in the Family: Researchers Search for Defective Gene in 5-in-1 Million Case

(Detroit Free Press) Jan 30, 2011 - When she was 8 years old, Rachel Ducusin had sore throats all the time, and a swelling on the right side of her neck.
read article 

New Induced Stem Cells May Unmask Cancer at Earliest Stage

(University of Wisconsin-Madison) Feb 4, 2011 - By coaxing healthy and diseased human bone marrow to become embryonic-like stem cells, a team of Wisconsin scientists has laid the groundwork for observing the onset of the blood cancer leukemia in the laboratory dish.
read press release 

Generic Drug May Improve the Effectiveness of Cancer Nanotherapies

(MGH) Feb 2, 2011 - Low doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment.
read press release